MRVI PE Ratio & Valuation,Is MRVI Overvalued

MRVI Relative Valuation

MRVI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRVI is overvalued; if below, it's undervalued.

Historical Valuation

Maravai LifeSciences Holdings Inc (MRVI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.66 is considered Undervalued compared with the five-year average of 1165.29. The fair price of Maravai LifeSciences Holdings Inc (MRVI) is between 51.82 to 55.54 according to relative valuation methord. Compared to the current price of 3.60 USD , Maravai LifeSciences Holdings Inc is Undervalued By 93.05%.

Relative Value

Fair Zone

51.82-55.54

Current Price：3.60

93.05%

Undervalued

-15.98

-412.39

EV/EBITDA

Maravai LifeSciences Holdings Inc. (MRVI) has a current EV/EBITDA of -412.39. The 5-year average EV/EBITDA is -10.78. The thresholds are as follows: Strongly Undervalued below -196.08, Undervalued between -196.08 and -103.43, Fairly Valued between 81.87 and -103.43, Overvalued between 81.87 and 174.52, and Strongly Overvalued above 174.52. The current Forward EV/EBITDA of -412.39 falls within the Strongly Undervalued range.

-14.93

EV/EBIT

Maravai LifeSciences Holdings Inc. (MRVI) has a current EV/EBIT of -14.93. The 5-year average EV/EBIT is 54.11. The thresholds are as follows: Strongly Undervalued below -165.81, Undervalued between -165.81 and -55.85, Fairly Valued between 164.07 and -55.85, Overvalued between 164.07 and 274.04, and Strongly Overvalued above 274.04. The current Forward EV/EBIT of -14.93 falls within the Historic Trend Line -Fairly Valued range.

2.66

Maravai LifeSciences Holdings Inc. (MRVI) has a current PS of 2.66. The 5-year average PS is 4.30. The thresholds are as follows: Strongly Undervalued below 0.88, Undervalued between 0.88 and 2.59, Fairly Valued between 6.00 and 2.59, Overvalued between 6.00 and 7.71, and Strongly Overvalued above 7.71. The current Forward PS of 2.66 falls within the Historic Trend Line -Fairly Valued range.

-36.77

P/OCF

Maravai LifeSciences Holdings Inc. (MRVI) has a current P/OCF of -36.77. The 5-year average P/OCF is 10.50. The thresholds are as follows: Strongly Undervalued below -32.65, Undervalued between -32.65 and -11.08, Fairly Valued between 32.08 and -11.08, Overvalued between 32.08 and 53.66, and Strongly Overvalued above 53.66. The current Forward P/OCF of -36.77 falls within the Strongly Undervalued range.

-19.93

P/FCF

Maravai LifeSciences Holdings Inc. (MRVI) has a current P/FCF of -19.93. The 5-year average P/FCF is 7.00. The thresholds are as follows: Strongly Undervalued below -75.51, Undervalued between -75.51 and -34.25, Fairly Valued between 48.26 and -34.25, Overvalued between 48.26 and 89.52, and Strongly Overvalued above 89.52. The current Forward P/FCF of -19.93 falls within the Historic Trend Line -Fairly Valued range.

Maravai LifeSciences Holdings Inc (MRVI) has a current Price-to-Book (P/B) ratio of 2.13. Compared to its 3-year average P/B ratio of 2.31 , the current P/B ratio is approximately -7.91% higher. Relative to its 5-year average P/B ratio of 9.00, the current P/B ratio is about -76.39% higher. Maravai LifeSciences Holdings Inc (MRVI) has a Forward Free Cash Flow (FCF) yield of approximately -12.70%. Compared to its 3-year average FCF yield of 5.30%, the current FCF yield is approximately -339.53% lower. Relative to its 5-year average FCF yield of 6.91% , the current FCF yield is about -283.79% lower.

2.13

P/B

Median3y

2.31

Median5y

9.00

-12.70

FCF Yield

Median3y

5.30

Median5y

6.91

Competitors Valuation Multiple

The average P/S ratio for MRVI's competitors is 156.52, providing a benchmark for relative valuation. Maravai LifeSciences Holdings Inc Corp (MRVI) exhibits a P/S ratio of 2.66, which is -98.3% above the industry average. Given its robust revenue growth of -39.69%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MRVI decreased by 33.94% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.63 to -4.28.

The secondary factor is the Revenue Growth, contributed -39.69%to the performance.

Overall, the performance of MRVI in the past 1 year is driven by P/E Change. Which is more unsustainable.

-39.69%

69.03M → 41.63M

Revenue Growth

-56.68%

-249.84 → -108.23

Margin Expansion

62.43%

-2.63 → -4.28

P/E Change

-33.94%

5.45 → 3.60

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Maravai LifeSciences Holdings Inc (MRVI) currently overvalued or undervalued?

What is Maravai LifeSciences Holdings Inc (MRVI) fair value?

MRVI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Maravai LifeSciences Holdings Inc (MRVI) is between 51.82 to 55.54 according to relative valuation methord.

How does MRVI's valuation metrics compare to the industry average?

The average P/S ratio for MRVI's competitors is 156.52, providing a benchmark for relative valuation. Maravai LifeSciences Holdings Inc Corp (MRVI) exhibits a P/S ratio of 2.66, which is -98.30% above the industry average. Given its robust revenue growth of -39.69%, this premium appears unsustainable.

What is the current P/B ratio for Maravai LifeSciences Holdings Inc (MRVI) as of Dec 15 2025?

As of Dec 15 2025, Maravai LifeSciences Holdings Inc (MRVI) has a P/B ratio of 2.13. This indicates that the market values MRVI at 2.13 times its book value.

What is the current FCF Yield for Maravai LifeSciences Holdings Inc (MRVI) as of Dec 15 2025?

As of Dec 15 2025, Maravai LifeSciences Holdings Inc (MRVI) has a FCF Yield of -12.70%. This means that for every dollar of Maravai LifeSciences Holdings Inc’s market capitalization, the company generates -12.70 cents in free cash flow.

What is the current Forward P/E ratio for Maravai LifeSciences Holdings Inc (MRVI) as of Dec 15 2025?

As of Dec 15 2025, Maravai LifeSciences Holdings Inc (MRVI) has a Forward P/E ratio of -15.98. This means the market is willing to pay $-15.98 for every dollar of Maravai LifeSciences Holdings Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Maravai LifeSciences Holdings Inc (MRVI) as of Dec 15 2025?

As of Dec 15 2025, Maravai LifeSciences Holdings Inc (MRVI) has a Forward P/S ratio of 2.66. This means the market is valuing MRVI at $2.66 for every dollar of expected revenue over the next 12 months.

MRVI Valuation